which modulate the innate immune system, including biologics and small
molecules. The company has signed some significant partnering and
collaborative deals, such as with Wyeth (USA). The company is based in Dublin
and also has laboratories in Lausanne, Switzerland.
About Novartis Venture Fund
The Novartis Venture Fund, established in 1996 currently manages over
$650 million in committed capital. NVF invests in companies which have the
potential to change a core therapeutic field or explore new business areas
that will be critical to patient care. Our primary interest is in the
development of novel therapeutics and platforms as well as medical devices,
diagnostics, and delivery systems. The Fund invests for financial objectives
at all stages, but prefers to invest in the early-stages of company
development. With eight investment professionals located in Basel,
Switzerland and Cambridge, MA the team has extensive experience in
pharmaceutical R&D and venture capital.
About Fountain Healthcare Partners
Fountain Healthcare Partners ("Fountain") is a life science focused
venture capital fund headquartered in Dublin, Ireland with a second office in
New York, US. Fountain specialises in making investments in biotechnology,
medical device, specialty pharma and diagnostic companies and allocates the
majority of its capital to Europe with a primary emphasis on Ireland.
Fountain launched its inaugural fund (Fountain Healthcare Partners I) in May
2008 with EUR75M in committed capital.
Inventages is one of the world's largest life-sciences, nutrition
Page: 1 2 3 4 Related biology technology :1
|SOURCE Opsona Therapeutics Ltd|
Copyright©2009 PR Newswire.
All rights reserved
. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA2
. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review3
. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation4
. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway5
. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 20076
. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer7
. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials8
. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination9
. Amsterdam Molecular Therapeutics Reports Half Year Results 200710
. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member11
. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug